Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma

Gynecologic Oncology

Volumn 66, Issue 2, 1997, Pages 268-274

  Kohler U ^a   Hiller, K ^a   Martin, R ^b   Langanke, D ^a   Naumann, G ^a   Bilek, K ^a   Janicke F ^c   Schmitt, M ^c  

^a UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY;

EID: 0031213704     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1997.4751     Document Type: Article

References (27)

1. Gleeson N, Gronsalves R, Bonnar J. The plasminogen activator urokinase and its inhibitor PAI-1 in the endometrial cancer. Gynecol Oncol. 47:1992;58-61.
2. Johnson M D, Torri J A, Lippmann M E, Dickson R B. The role of cathepsin D in the invasiveness of human breast cancer cells. Cancer Res. 53:1993;873-877.
3. Spyratos F, Maudelonde T, Brouillet J-P, Brunet M, Defrenne A, Andreieu C, Hacene K, Desplaces A, Rouesse J, Rochefort H. Cathepsin D: An independent prognostic factor for metastasis of breast cancer. Lancet. II:1989;1115-1118.
4. Dano K, Andreasen P A, Grohndahl-Hansen J, Kristensen P, Nielsen L S, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 44:1985;139-266.
5. Varani J, McKeever P, Fligiel S EG, Sitrin R G. Plasminogen activator production by human tumor cells: Effect on tumor cell-extracellular matrix interactions. Int J Cancer. 40:1985;772-777.
6. Kristensen P, Larsson L I, Nielsen L S, Grohndahl-Hansen J, Andreasen P A, Dano K. Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 168:1984;33-37.
7. F, Blasi, 1988, Surface receptors for urokinase plasminogen activator, Fibrinolysis, 2, 73, 84.
8. Petersen L C, Lund L R, Nielsen L S, Dano K, Skriver L. One chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. J Biol Chem. 263:1988;11189-11195.
9. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 24:1993;195-208.
10. Kobayashi H, Schmitt M, Goretzki L, Chucholowski N, Calvette J, Kramer M, Günzler W A, Jänicke F, Graeff H. Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA). Biol Chem. 266:1991;5147-5152.
11. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator: Biological and clinical significance. Biol Chem Hoppe Seyler. 373:1992;611-622.
12. Dano K, Behrendt N, Brnner N, Ellis V, Ploug M, Pyke C. The urokinase receptor protein, structure and role in plasminogen activation and cancer invasion. Fibrinolysis. 8:1994;189-203.
13. Ossowski L, Clunie G, Masucci M T, Blasi F. In vivo paracrine interaction between urokinase and its receptor effect on tumor cell invasion. J Cell Biol. 115:1991;1107-1112.
14. Grondahl-Hansen J, Peters H A, van Putten W LJ, Look M P, Pappot H, Ronne E, Dano K, Klijn J GM, Brnner N, Foekens J A. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1:1995;1079-1087.
15. Pyke C, Graem E, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brnner N, Dano K. Receptor for urokinase is present in tumorassociated macrophages in ductal breast carcinoma. Cancer Res. 53:1993;1911-1915.
16. Bianchi E, Cohen R L, Thor A T, Todd R F III, Mizukami F, Lawrence D A, Ljung B M, Shuman M A, Smith H S. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res. 54:1994;861-866.
17. Del Vecchio S, Stoppelli M P, Carriero M V, Fonti R, Massa O, Young Li P, Botti G, Cerra M, Aiuto G, Esposito G, Salvatore M. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinase levels. Cancer Res. 53:1993;3198-3206.
18. Grohndahl-Hansen J, Christensen I J, Rosenquist C, Brünner N, Mouridsen H T, Dano K, Blichert-Torft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:1993;2513-2521.
19. Saito K, Nagashima M, Iwata M, Hamada H, Sumiyoshi K, Takada Y, Takada A. The concentration of tissue plasminogen activator and urokinase in plasma and tissue of patients with ovarian and uterine tumors. Thromb Res. 58:1990;353-366.
20. Ossowski L, Reich E. Antibodies to plasminogen activator inhibit human tumor metastasis. Cell. 35:1983;611-619.
21. Koelbl H, Kirchheimer J, Tatra G, Christ G, Binder B. Increased plasma levels of urokinase-type plasminogen activator with endometrial and cervical cancer. Obstet Gynecol. 72:1988;252-255.
22. Kirchheimer J C, Kölbl H, Tatra G, Binder B R. Relationship between plasma levels of components of the fibrinolytic system and acute-phase reactants in patients with uterine malignancies. Eur J Clin Invest. 20:1990;79-84.
23. Camiolo S M, Markus G, Piver M S. Plasminogen activator content of gynecological tumors and their metastases. Gynecol Oncol. 26:1987;364-373.
24. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis. 4:1990;69-78.
25. Konno H, Tanaka T, Maruo Y, Nishino N, Nakamura S, Baba S, Takada A. Correlation between tumor proliferation and tumor tissue level of urokinase-type plasminogen activator. Eur Surg Res. 25:1993;239-244.
26. Sugimura M, Kobayashi H, Kanayama N, Terao T. Clinical significance of urokinase-type plasminogen activator (uPA) in invasive cervical cancer of the uterus. Gynecol Oncol. 46:1992;330-336.
27. Reilly D, Christensen L, Duch M, Nolan N, Duffy M, Andreasen P A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer. 50:1992;208-214.